<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955678</url>
  </required_header>
  <id_info>
    <org_study_id>ZG-801-02</org_study_id>
    <nct_id>NCT04955678</nct_id>
  </id_info>
  <brief_title>A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia</brief_title>
  <official_title>ZG-801 Phase III Trial - Randomized, Double-blind, Placebo-controlled Trial of ZG-801 in Patients With Hyperkalemia -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of ZG-801 to placebo in Japanese&#xD;
      hyperkalemia patients whose serum potassium value becomes normal in the Run-in period by&#xD;
      comparing the change in the value at the Double-blind period week 4, and to further evaluate&#xD;
      the efficacy and safety of ZG-801 in Japanese hyperkalemia patients administrated ZG-801 for&#xD;
      maximum 9 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum potassium value at Double-blind period week4</measure>
    <time_frame>Double-blind period baseline to Double-blind period week4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of serum potassium value within 3.5 mEq/L to &lt; 5.1 mEq/L or within 3.5 mEq/L to &lt;5.5 mEq/L in Double-blind Period</measure>
    <time_frame>Double-blind period baseline to Double-blind period week4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Non-maintenance of Serum Potassium Value in Double-blind Period</measure>
    <time_frame>Double-blind period baseline to Double-blind period week4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAASi dose sustaining proportion</measure>
    <time_frame>Double-blind period baseline to Double-blind period week4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Potassium Value</measure>
    <time_frame>Run-in period baseline to Run-in period week 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>ZG-801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes</intervention_name>
    <description>ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.</description>
    <arm_group_label>ZG-801</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients whose serum potassium value (local) at the Run-in period baseline is&#xD;
             â‰¥5.5mEq/L, &lt; 6.5 mEq/L&#xD;
&#xD;
          -  Age 20 - 80 years old at informed consent&#xD;
&#xD;
          -  Patients who understand an overview of the study and voluntarily consented to&#xD;
             participate in the study by documents.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Patients determined to require emergency treatment for hyperkalemia at the Run-in&#xD;
             period baseline&#xD;
&#xD;
          -  Patients with poorly controlled blood pressure&#xD;
&#xD;
          -  Patients with heart failure in New York Heart Association Class IV&#xD;
&#xD;
          -  Patients who have experienced heart transplant, liver transplant or kidney transplant&#xD;
             or who are predicted that the need for them will occur during the study&#xD;
&#xD;
          -  Patients who have taken any of the following medication within 7 days prior to the&#xD;
             Run-in period baseline or currently administrated.&#xD;
&#xD;
               1. Sodium polystyrene sulfonate&#xD;
&#xD;
               2. Calcium polystyrene sulfonate&#xD;
&#xD;
               3. Sodium zirconium cyclosilicate hydrate&#xD;
&#xD;
               4. Potassium supplement&#xD;
&#xD;
          -  Patients with or who have experienced a severe swallowing disorder, moderate to severe&#xD;
             gastroparesis, severe constipation, bowel obstruction, incarceration, abnormal&#xD;
             post-operative bowel motility disorders or severe gastrointestinal disorders. In&#xD;
             addition, patients who have experienced bariatric surgery or major gastrointestinal&#xD;
             surgery (e.g., bowel resection).&#xD;
&#xD;
          -  Patients suspected to be with transient high potassium value.(ex. caused by dietary&#xD;
             effects only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuke Tomioka</last_name>
    <role>Study Director</role>
    <affiliation>Zeria Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeria R&amp;D</last_name>
    <phone>+81-33611-0276</phone>
    <email>801registry@zeria.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Hitachinaka</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeria Investigative PI</last_name>
      <phone>+81-33611-0276</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorbitol</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

